Hirtle Callaghan & Co’s Amgen AMGN Stock Holding History

Hirtle Callaghan & Co’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-2,000	Closed	-$389K	–	76
2018 Q4	$389K	Hold	2,000	–	–	0.03%	68
2018 Q3	$415K	Hold	2,000	–	–	0.04%	67
2018 Q2	$369K	Hold	2,000	–	–	0.03%	73
2018 Q1	$341K	Hold	2,000	–	–	0.03%	75
2017 Q4	$348K	Hold	2,000	–	–	0.03%	75
2017 Q3	$373K	Buy	+2,000	New	+$354K	0.04%	67
2016 Q4	–	Sell	-2,000	Closed	-$334K	–	152
2016 Q3	$334K	Hold	2,000	–	–	0.07%	68
2016 Q2	$304K	Hold	2,000	–	–	0.06%	68
2016 Q1	$300K	Buy	2,000 +645	+48%	+$95.8K	0.06%	72
2015 Q4	$220K	Buy	1,355 +271	+25%	+$42.6K	0.05%	49
2015 Q3	$150K	Hold	1,084	–	–	0.03%	97
2015 Q2	$166K	Buy	+1,084	New	+$174K	0.06%	96
2015 Q1	–	Sell	-5,782	Closed	-$921K	–	31
2014 Q4	$921K	Buy	5,782 +42	+0.7%	+$6.54K	0.21%	73
2014 Q3	$806K	Buy	5,740 +9	+0.2%	+$1.18K	0.13%	80
2014 Q2	$678K	Sell	5,731 -2	-0%	-$232	0.09%	122
2014 Q1	$707K	Buy	5,733 +2,006	+54%	+$243K	0.12%	107
2013 Q4	$425K	Buy	3,727 +1,801	+94%	+$205K	0.06%	145
2013 Q3	$216K	Buy	+1,926	New	+$209K	0.03%	215

Other funds holding AMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Hirtle Callaghan & Co's AMGN Position: Q1 2019 in Review

Hirtle Callaghan & Co sold out of Amgen (AMGN) in Q1 2019, closing a stake of 2,000 shares — an estimated $389K sold.

Hirtle Callaghan & Co first reported a position in AMGN in Q3 2013 and held it in 18 quarters. The position peaked at $921K in Q4 2014. 1,886 funds tracked by Wall St. Rank hold AMGN as of Q1 2019.

Hirtle Callaghan & Co reported no remaining Amgen position as of Q1 2019 after selling out during the quarter.
Hirtle Callaghan & Co sold 2,000 Amgen shares in Q1 2019, an estimated $389K.
Hirtle Callaghan & Co first reported a position in Amgen in Q3 2013 and held it in 18 quarters.
Hirtle Callaghan & Co's Amgen position peaked at $921K in Q4 2014.
1,886 funds tracked by Wall St. Rank held Amgen as of Q1 2019.

Based on Hirtle Callaghan & Co's 13F filing for Q1 2019, filed 14 May 2019.